BBP-631

N/A

Report date: 2023/10/26 17:03:46

Base Information

Drug NameBBP-631
Drug Alias NameBBP-631
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionSteroid 21 hydroxylase gene transference
TargetsSteroid 21 hydroxylase
Therapy Area/IndicationsAdrenal Hyperplasia, Congenital
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLife Technologies IncBridgebio Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Resilience IncAdrenas Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAdrenal Hyperplasia, Congenital
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A